Literature DB >> 31732547

Systemic Artery Aneurysms and Kawasaki Disease.

Qu-Ming Zhao1,2, Chen Chu1,2, Lin Wu1, Xue-Cun Liang1, Shu-Na Sun1, Lan He3, Lu Zhao1, Feng Wang1, Guo-Ying Huang1, Conway Niu4, Fang Liu3.   

Abstract

BACKGROUND: Coronary artery aneurysms (CAAs) are a well-known complication of Kawasaki disease (KD), but there are no data on incidence or outcomes of systemic artery aneurysms (SAAs) in the current era.
METHODS: From April 1, 2016, to March 31, 2019, we screened for SAAs in 162 patients with KD at risk for SAAs with magnetic resonance angiography or peripheral angiography and analyzed incidence and early outcomes of SAAs.
RESULTS: Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23 of 162) in patients who were screened at 1 month after onset. The proportion of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with KD. The median age at onset of KD with SAAs was 5 months. All patients with SAAs had CAAs, with z scores >8. Of patients with giant CAAs, 38.6% (17 of 44) had SAAs. A total of 129 SAAs occurred in 17 different named arteries. The most common sites for SAAs were the axillary (18.6%), common iliac (12.4%), and brachial (11.6%) arteries. During a median follow-up time of 6 months, 92.9% (79 of 85) of SAAs had some degree of regression, with 80% (68 of 85) of SAAs returning to normal. The overall regression rate was higher for medium to large SAAs than for medium to giant CAAs.
CONCLUSIONS: Although the incidence of SAAs may not be as dramatically reduced as we expected compared with previous data, SAAs have a high regression rate during short-term follow-up.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2019        PMID: 31732547     DOI: 10.1542/peds.2019-2254

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

1.  Evaluating the time-varying risk of hypertension, cardiac events, and mortality following Kawasaki disease diagnosis.

Authors:  Jennifer J Y Lee; Brian M Feldman; Brian W McCrindle; Ping Li; Rae Sm Yeung; Jessica Widdifield
Journal:  Pediatr Res       Date:  2022-08-24       Impact factor: 3.953

2.  Kawasaki disease does not affect coronaries alone: large vessels can be involved as well.

Authors:  Murugan Sudhakar; Manphool Singhal; Gummadi Anjani; Prabal Barman; Ningthoujam Anilbala; Pandiarajan Vignesh; Surjit Singh
Journal:  Clin Rheumatol       Date:  2022-03-08       Impact factor: 3.650

Review 3.  Kawasaki Disease: Pathology, Risks, and Management.

Authors:  Mitsuru Seki; Takaomi Minami
Journal:  Vasc Health Risk Manag       Date:  2022-06-10

4.  Recurrent brachial artery aneurysm repair in a child managed with Gore-Tex conduit reinforcement.

Authors:  Jordan Kaplan; Ryan Wagner; Lindsey E White; William C Pederson
Journal:  J Vasc Surg Cases Innov Tech       Date:  2021-02-09

5.  Giant bilateral axillary artery aneurysms with left complete obstructive thrombus in intravenous immunoglobulin-sensitive Kawasaki disease: a case report.

Authors:  Chen Chu; Lan He; Yi-Xiang Lin; Li-Ping Xie; Fang Liu
Journal:  Pediatr Rheumatol Online J       Date:  2021-11-08       Impact factor: 3.054

6.  Pitfall for systemic artery aneurysms evaluation using electrocardiogram-gated subtracted three-dimensional fast spin echo sequence of magnetic resonance imaging in patients with Kawasaki disease.

Authors:  Haruki Nonaka; Takanori Masuda; Masami Yoneyama; Masahiro Tahara; Mio Okano; Yuko Morikawa; Kazuya Sanada; Tomoyasu Sato
Journal:  Radiol Case Rep       Date:  2022-03-02

7.  Kawasaki Disease Complicated by Late-Onset Fatal Cerebral Infarction: A Case Report and Literature Review.

Authors:  Lin Wang; Hongyu Duan; Kaiyu Zhou; Yimin Hua; Xiaoliang Liu; Chuan Wang
Journal:  Front Pediatr       Date:  2021-05-19       Impact factor: 3.418

8.  Neonatal Kawasaki disease with multiple arterial aneurysms: a case report.

Authors:  Qu-Ming Zhao; Xue-Cun Liang; Lin Wu; Fang Liu
Journal:  Pediatr Rheumatol Online J       Date:  2020-06-15       Impact factor: 3.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.